The clinical presentation of GM1 gangliosidosis varies dramatically between patients depending on the underlying GLB1 mutations.2 Patients expressing residual β-gal may present with neurological signs at any age and variable degrees of somatic disease. This evidence concerns the gene GLB1 and GM1 gangliosidosis.